Teijin Limited

Other

Tatsuki Shiota

Noriaki Endo

Christine M Tarby

Kenichiro Kataoka

Takaharu Tsutsumi

Wilna J Moree

Masaki Sudoh

Yumiko Muroga

Takahiko Hada

Takuya Morita

Steven L Teig

Minoru Imai

Osami Takenouchi

Minoru Furuya

Ken-ichiro Kataoka

Ryo Sogawa

Takashi Kamimura

Hisao Yamaguchi

Hiroko Tanaka

Takumi Takeyasu

Hirofumi Tanabe

Mikio Ota

Tsutomu Mochizuki

Jonathan W Greene

Tomohiro Ohta

Yasuhiro Takano

Toru Minoshima

Akinobu Nakanishi

Tomonori Yokoyama

Hideki Horiuchi

Masatoshi Kano

Doug Barnum

Michele Ramirez Weinhouse

Shinsuke Yamagami

Fuminori Miyagi

A medicine containing, as an active ingredient, a cyclic amine derivative represented by the following formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable Cto Calkyl addition salt thereof. The medicine has an action for treating or preventing diseases in which CCR3 participates, such as asthma and allergic rhinitis.

Cyclic amine CCR3 antagonist

This invention provides remedies or prophylactics for diseases in association with chemokines such as MIP-1 &#x3b1; and/or MCP-1. Namely, remedies or prophylactics for diseases in association with the chemokines such as rheumatoid arthritis or nephritis contain, as the active ingredient, cyclic amine derivatives represented by the following formula (I), pharmaceutically acceptable acid addition salts thereof or pharmaceutically acceptable C-Calkyl addition salts thereof.

Remedies or prophylactics for diseases in association with chemokines

Cyclic diamines of formula (I) or their pharmacologically acceptable acid addition salts, and their medical applications are described. These compounds inhibit the action of chemokines such as MIP-1a and/or MCP-1 on target cells, and are useful as a therapeutic drug and/or preventative drug in diseases, such as atherosclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissue.

Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists

Cyclic amine derivatives and their use as drugs

Prostaglandins and processes for production thereof

A benzopyran derivative represented by the formula (I) or its pharmaceutically acceptable salt: ##STR1## wherein either one of X and Y stands for the following formula ##STR2## and the other one of X and Y and R.sup.1 -R.sup.10 stand for various substituents, and ACAT inhibitor, anti-hyperlipidemia agent and anti-atherosclerosis agent compositions containing the same as an active ingredient.

Benzopyran derivative, process for producing the same and pharmaceutical

Pharmaceutical compositions containing a benzoxazole compound and a 2,3-dihydrobenzofuran compound represented by the following formula (I) and its pharmaceutically acceptable salt: ##STR1## In the formula, any one of P, Q, R and S is a group represented by the formula: ##STR2## and R.sub.1, R.sub.2 and the reining three substituents out of the substituents P to S each independently stand for various substituents. These compositions are used as an ATCAT inhibitor or for treating hyperlipidemia and atherosclerosis.

Benzoxa condensed ring compounds, process for producing the same and

Growing community of inventors

Hino, Japan

Tatsuki Shiota